Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.48
-1.9%		$12.47
$9.62
▼
$21.34
$828.10M-0.0124,278 shs12,357 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-1.88%+0.17%+13.89%-6.51%-22.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.48
-1.9%		$12.47
$9.62
▼
$21.34
$828.10M-0.0124,278 shs12,357 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-1.88%+0.17%+13.89%-6.51%-22.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.20
Hold$38.67236.82% Upside

Current Analyst Ratings Breakdown

Latest MCM, PHAR, BKY, and SAVE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/3/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
7/31/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/30/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$376.13M2.16$0.20 per share58.34$3.95 per share2.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$2.85M$0.1295.6738.27N/A2.51%3.40%1.90%11/5/2026 (Estimated)

Latest MCM, PHAR, BKY, and SAVE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$0.0630$0.02-$0.0430$0.02$99.52 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.34
3.01
2.31

Institutional Ownership

CompanyInstitutional Ownership
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28070.78 million69.31 millionNot Optionable

Recent News About These Companies

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Increase in Short Interest
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharming-group-nv-sponsored-adr-nasdaq-phar-sees-large-increase-in-short-interest-2026-08-27/
Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-up-whats-next-2026-08-26/
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nv-sponsored-adr-nasdaqphar-short-interest-up-930-in-july-2026-08-16/
Pharming introduces Joenja in Japan for adult and paediatric patients with activated PI3K delta syndrome aged 4 and older
August 14, 2026  |  pharmabiz.comP
Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299602-pharming-group-n-v-pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-pediatric-patients-with-apds-aged-4-and-older-399.htm
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nv-sponsored-adr-nasdaqphar-given-average-rating-of-hold-by-brokerages-2026-08-13/
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
August 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-pediatric-patients-with-apds-aged-4-and-older-1036452444
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nasdaqphar-shares-gap-down-should-you-sell-2026-08-12/
Pharming Group (PHAR) Stock Price, Quote, News & History
August 12, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PHAR
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Time to Buy?
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nasdaqphar-sees-unusually-high-trading-volume-time-to-buy-2026-08-11/
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pharming-group-phar-securities-investigation-notice---levi--korsinsky-302845698.html
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 5, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/05/10426036.htm
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
August 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260805570152/en/securities-fraud-investigation-into-pharming-group-n.v.-phar-announced-%e2%80%93-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r.-cruz/
Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nasdaqphar-shares-gap-up-time-to-buy-2026-08-05/
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339444/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-pharming-group-phar.html
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
August 4, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/04/10425106.htm
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pharming-group-participate-canaccord-genuity-060000797.html
Canaccord Genuity Group Forecasts Strong Price Appreciation for Pharming Group (NASDAQ:PHAR) Stock
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/canaccord-genuity-group-forecasts-strong-price-appreciation-for-pharming-group-nasdaqphar-stock-2026-08-03/
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-pharming-group-lowered-by-hc-wainwright-2026-08-03/
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)
July 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pharming-group-investigation-notice-levi--korsinsky-notifies-investors-of-pending-investigation-into-pharming-group-phar-302840307.html
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928101-pharming-group-n-v-phar-q2-2026-earnings-call-transcript

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
CVS Health logo displayed above a pharmacy counter with prescription bottles and a bandage box on the counter.
One Comment on CVS's Earnings Call Sent the Stock Tumbling
By Chris Markoch | August 7, 2026
Three-panel image showing a refrigerated delivery truck, vials packed in ice, and a worker in a cold storage warehouse.
GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
By Chris Markoch | August 4, 2026
Glass vials, flasks, test tubes, and a microscope in a laboratory setting with scientific analysis equipment.
Insiders Are Betting Big on These 3 Healthcare Stocks
By Thomas Hughes | August 31, 2026
Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$11.48 -0.22 (-1.88%)
As of 08/31/2026 04:00 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas